News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Alendronate to be subsidised

27 October 2005

Alendronate to be subsidised to help prevent fractures

Many more people with osteoporosis will be able to have subsidised access to alendronate from 1 October 2005.

The decision by government drug-funder PHARMAC includes a significant access widening which will see alendronate (Fosamax) available for patients at high risk of fractures from osteoporosis, as well as more of those who have already suffered fractures.

In all, PHARMAC estimates that the new criteria will make subsidised alendronate accessible to up to 100,000 people. Under existing criteria, approximately 20,000 patients are currently being treated with alendronate.

PHARMAC’s acting medical director Dilky Rasiah says extending the subsidised use of alendronate to help prevent fractures is a significant step forward.

“Up until now subsidised access has only been allowed for those patients who have already had both a fracture and a high risk of a future fracture. So we are delighted to be able to help other patients at high risk to prevent fractures occurring,” says Dr Rasiah.

“In addition, we have ‘lowered the bar’ to enable people who have had fractures, and have lower bone mineral density, to have subsidised alendronate. This decision will mean that we will have wider subsidised access to alendronate in New Zealand than in Australia, so this is great news for New Zealanders at high risk of fragility fractures.”

Osteoporosis increases the risk of bones fracturing through a reduction in bone mineral density. It is prevalent among women and older people, affecting at least 137,000 New Zealanders, which includes 30% of all women aged 60 years and over and more than half of women aged 80 years and over.

PHARMAC estimates that the change in access criteria will result in expenditure on alendronate increasing to nearly $17 million per annum over the next three years.

Providing greater access to alendronate is the latest medicine funding decision by PHARMAC and follows other recent decisions to widen access to the diabetes medicine pioglitazone, the transplant rejection drug mycophenolate, the breast cancer medicines known as aromatase inhibitors, and to list the injected form of the antipsychotic medicine risperidone.


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Reuben Moss' Property is Theft! & Kaitani at The Physics Room

Property is Theft! continues Moss’ interest in the contemporary urban environment as a space controlled by pulsing and unequal flows of capital and labour. Kaitani features work by the University of Canterbury Fijian Students Association and Kulimoe’anga Stone Maka. More>>

Handcrafted Form: Rare Treasures From Japan

This unique exhibition at Expressions Whirinaki represents 90 everyday objects made by contemporary Japanese artisans who employ various traditional craft techniques made in regional workshops. The works used in daily life are crafted from raw materials with techniques appropriate to bringing out the best of its medium, balancing ease of use with aesthetic appeal. More>>

Howard Davis Article: A Musical Axis - Brahms, Wagner, Sibelius

Brahms' warm and exquisitely subtle Symphony No. 3 in F major, Wagner's irrepressibly sentimental symphonic poem Siegfried Idyll, and Sibelius' chilling and immensely challenging Violin Concerto in D minor exemplify distinct stages of development in a tangled and convoluted series of skirmishes that came to define subsequent disputes about the nature of post-Romantic orchestral writing well into the following century. More>>

Scoop Review Of Books: A Pale Ghost Writer

Reviewed by Ruth Brassington, Richard Flanagan's new novel is about a novelist hastily ghost-writing the biography of a crook about to go to trial. The reader is kept on a cliff-edge, as the narrator tries to get blood out of his stone man. More>>

New Zealand Wars Commemoration: Witi Ihimaera's Sleeps Standing Moetū

The second of several articles to mark Rā Maumahara, remembering the New Zealand Land Wars. The first was a Q&A with Vincent O’Malley, author of The Great War for New Zealand: Waikato 1800–2000. More>>




  • Wellington
  • Christchurch
  • Auckland